* Recursion Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on May 9 for the period ending March 31 2024
* The Salt Lake City Utah-based company is expected to report a 4.3% increase in revenue to $12.65 million from $12.13 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Recursion Pharmaceuticals Inc is for a loss of 42 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $12.50, above its last closing price of $8.79.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.46 -0.45 -0.42 Beat 6.4
Sep. 30 2023 -0.38 -0.38 -0.43 Missed -11.7
Jun. 30 2023 -0.38 -0.37 -0.38 Missed -1.5
Mar. 31 2023 -0.34 -0.35 -0.34 Beat 2.3
Dec. -0.31 -0.29 -0.31 Missed -6.9
31 2022
Jan. 1 0001 -0.38 -0.38 -0.35 Beat 7.3
Jun. 30 2022 -0.38 -0.37 -0.38 Missed -1.8
Mar. 31 2022 0.12 0.10 -0.33 Missed -430
This summary was machine generated May 8 at 02:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments